188 related articles for article (PubMed ID: 35880594)
41. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan.
Koriyama C; Akiba S; Itoh T; Kijima Y; Sueyoshi K; Corvalan A; Herrera-Goepfer R; Eizuru Y
Int J Mol Med; 2002 Nov; 10(5):635-9. PubMed ID: 12373307
[TBL] [Abstract][Full Text] [Related]
43. Genetic landscape and PD-L1 expression in Epstein-Barr virus-associated gastric cancer according to the histological pattern.
Park JH; Cho HJ; Seo J; Park KB; Kwon YH; Bae HI; Seo AN; Kim M
Sci Rep; 2023 Nov; 13(1):19487. PubMed ID: 37945587
[TBL] [Abstract][Full Text] [Related]
44. PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.
Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Lee HS; Jeon S; Yoo TK; Park WC; Yoon CI
Sci Rep; 2021 Oct; 11(1):19555. PubMed ID: 34599199
[TBL] [Abstract][Full Text] [Related]
45. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
47. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
[TBL] [Abstract][Full Text] [Related]
48. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
49. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1
Saito R; Abe H; Kunita A; Yamashita H; Seto Y; Fukayama M
Mod Pathol; 2017 Mar; 30(3):427-439. PubMed ID: 27934877
[TBL] [Abstract][Full Text] [Related]
50. Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal.
Ribeiro J; Oliveira A; Malta M; Oliveira C; Silva F; Galaghar A; Afonso LP; Neves MC; Medeiros R; Pimentel-Nunes P; Sousa H
World J Gastroenterol; 2017 Oct; 23(40):7292-7302. PubMed ID: 29142476
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and characteristics of Epstein-Barr virus associated gastric carcinoma in Gansu Province, Northwest China with mRNA expression of glycoprotein BMRF2.
Guo C; Wei J; Scott RS; Chen Y; Chen Z; Zhao W; Zhang C; Wang B; Chai C; Dai G; Li M; Zhang F
J Med Virol; 2020 Mar; 92(3):356-363. PubMed ID: 31663617
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
53. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E
Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066
[TBL] [Abstract][Full Text] [Related]
54. Loss of viral genome with altered immune microenvironment during tumour progression of Epstein-Barr virus-associated gastric carcinoma.
Kondo A; Shinozaki-Ushiku A; Rokutan H; Kunita A; Ikemura M; Yamashita H; Seto Y; Nagae G; Tatsuno K; Aburatani H; Koinuma D; Ushiku T
J Pathol; 2023 Jun; 260(2):124-136. PubMed ID: 36806225
[TBL] [Abstract][Full Text] [Related]
55. EBV-Associated Gastric Cancer; An In Situ Hybridization Assay on Tissue Microarray: A Multi-Region Study from Four Major Provinces of Iran.
Abolhasani M; Mohseni AO; Shakeri R; Khavanin A; Khajehei M; Omidi A; Geramizadeh B; Shafigh E; Naghshvar F; Fathizadeh P; Taghizadehgan L; Gharib A; Gulley ML; Dawsey SM; Malekzadeh R; Rabkin CS; Vasei M
Arch Iran Med; 2024 Apr; 27(4):191-199. PubMed ID: 38685845
[TBL] [Abstract][Full Text] [Related]
56. Epstein-Barr virus-associated gastric adenocarcinomas among Koreans.
Shin WS; Kang MW; Kang JH; Choi MK; Ahn BM; Kim JK; Sun HS; Min KW
Am J Clin Pathol; 1996 Feb; 105(2):174-81. PubMed ID: 8607441
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
59. P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas.
Ojima H; Saito K; Yamauchi H; Yamaki E; Idetu A; Hosouchi Y; Nishida Y; Tukada K; Kato H; Kuwano H
Anticancer Res; 2006; 26(2A):933-7. PubMed ID: 16619489
[TBL] [Abstract][Full Text] [Related]
60. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
